COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

cAMP Signaling and Muscle Adaptations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02557581
Recruitment Status : Unknown
Verified October 2017 by Morten Nielsen, University of Copenhagen.
Recruitment status was:  Recruiting
First Posted : September 23, 2015
Last Update Posted : October 26, 2017
Information provided by (Responsible Party):
Morten Nielsen, University of Copenhagen

Brief Summary:
The role of cAMP signaling mediated by beta2-adrenergic stimulation with agonists has been well-studied in skeletal muscles of animals. Studies in humans are scant and the scope of the present study is thus to investigate the role of cAMP signaling by beta2-adrenergic stimulation for muscle adaptations in humans.

Condition or disease Intervention/treatment Phase
Muscle Hypertrophy in Healthy Young Men Other: No training Other: Endurance training Other: Resistance Training Drug: Terbutaline Drug: Clenbuterol Drug: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Study Start Date : July 2015
Actual Primary Completion Date : June 30, 2017
Estimated Study Completion Date : October 2017

Arm Intervention/treatment
Experimental: Terbutaline
Beta2-adrenergic stimulation with terbutaline
Other: No training
Other: Endurance training
Other: Resistance Training
Drug: Terbutaline
Placebo Comparator: Placebo
Other: No training
Other: Endurance training
Other: Resistance Training
Drug: Placebo
Experimental: Clenbuterol
Beta2-adrenergic stimulation with clenbuterol
Other: No training
Drug: Clenbuterol

Primary Outcome Measures :
  1. Muscle hypertrophy (lean body mass in Kilograms) [ Time Frame: 2 days ]
    Lean body mass (kg) will be measured at two different days by Dual X-ray absorbance (DXA)

Secondary Outcome Measures :
  1. Energy turnover (ml/min or mmol/kg dry weight muscle) [ Time Frame: 1 day ]
    Pulmonary gas exchange and lactate and glycogen will be measured in muscle biopsies obtained before and after intense exercise

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy young men
  • 18-35 years of age
  • Informed consent
  • Active 2-5 hours of training pr. week
  • Maximal oxygen uptake (ml/min/kg) of 40-60
  • Lean body mass of 55-65 kg / Lean mass index 14-22 kg/m2

Exclusion Criteria:

  • Smoker
  • Allergy towards study drugs
  • Chronic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02557581

Layout table for location contacts
Contact: Morten Hostrup, PhD +4524474785

Layout table for location information
Department of Nutrition, Exercise and Sports Recruiting
Copenhagen, Denmark, 2100
Contact: Morten Hostrup, PhD    +4524474785   
Bispebjerg University Hospital Recruiting
Copenhagen, Denmark, 2400
Contact: Morten Hostrup, PhD    +4524474785   
Sponsors and Collaborators
University of Copenhagen
Layout table for additonal information
Responsible Party: Morten Nielsen, Post.Doc, University of Copenhagen Identifier: NCT02557581    
Other Study ID Numbers: TUD
First Posted: September 23, 2015    Key Record Dates
Last Update Posted: October 26, 2017
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathological Conditions, Anatomical
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action